Circadian rhythms, melatonin and depression

Current Pharmaceutical Design

Volumn 17, Issue 15, 2011, Pages 1459-1470

  Quera Salva, M A ^a   Hartley, S ^a   Barbot, F ^a   Alvarez, J C ^a   Lofaso, F ^a   Guilleminault, C ^b  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Circadian rhythms; Major depression disorder; Melatonin; Melatonin agonists

Indexed keywords

AGOMELATINE; FLUOXETINE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR; NEU P11; PAROXETINE; PLACEBO; RAMELTEON; ROZERAM; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SERTRALINE; TASIMELTEON; TIK 301; UNCLASSIFIED DRUG; VENLAFAXINE;

ALERTNESS; ANTERIOR HYPOTHALAMUS; AROUSAL; ARTICLE; BEDTIME DOSAGE; BIOLOGICAL RHYTHM; BIPOLAR DISORDER; CHRONOTHERAPY; CIRCADIAN RHYTHM; DEPRESSION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; INSOMNIA; MAJOR DEPRESSION; MOOD DISORDER; PHOTOTHERAPY; PRIORITY JOURNAL; QT PROLONGATION; SEASONAL AFFECTIVE DISORDER; SLEEP;

ACETAMIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL CLOCKS; CHRONOBIOLOGY DISORDERS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MELATONIN; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84856278625     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796197188     Document Type: Article

References (147)

1. Reinberg A, Halberg F. Circadian chronopharmacology. Annu Rev Pharmacol 1971; 11: 455-92.
2. Reinberg AE. Concepts in chronopharmacology. Annu Rev Pharmacol Toxicol 1992; 32: 51-66.
3. Klein DC, Moore RY. Pineal N-acetyltransferase and hydroxyindole- O-methyltransferase: control by the retinohypothalamic tract and the suprachiasmatic nucleus. Brain Res 1979; 174: 245-62.
4. Guillaumond F, Dardente H, Giguere V, Cermakian N. Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J Biol Rhythms 2005; 20: 391-403.
5. Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Hum Mol Genet 2006; 15 Spec No 2: R271-7.
6. Shearman LP, Sriram S, Weaver DR et al. Interacting molecular loops in the mammalian circadian clock. Science 2000; 288: 1013-9.
7. Borbely AA. A two process model of sleep regulation. Hum Neurobiol 1982; 1: 195-204.
8. Daan S, Beersma DG, Borbely AA. Timing of human sleep: recovery process gated by a circadian pacemaker. Am J Physiol 1984; 246: R161-83.
9. Viola AU, Archer SN, James LM et al. PER3 polymorphism predicts sleep structure and waking performance. Curr Biol 2007; 17: 613-8.
10. Franken P, Dijk DJ. Circadian clock genes and sleep homeostasis. Eur J Neurosci 2009; 29: 1820-9.
11. Lerner AB, Case JD, Takahashi Y, Lee TH. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Amer Chem Soc 1958; 80: 2587.
12. Ebadi M, Govitrapong P. Neural pathways and neurotransmitters affecting melatonin synthesis. J Neural Transm Suppl 1986; 21: 125-55.
13. Cagnacci A, Elliott JA, Yen SS. Melatonin: a major regulator of the circadian rhythm of core temperature in humans. J Clin Endocrinol Metab 1992; 75: 447-52.
14. Rajaratnam SM, Middleton B, Stone BM, Arendt J, Dijk DJ. Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. J Physiol 2004; 561: 339-51.
15. Altimus CM, Guler AD, Alam NM, et al. Rod photoreceptors drive circadian photoentrainment across a wide range of light intensities. Nat Neurosci 2010; 13: 1107-12.
16. Lall GS, Revell VL, Momiji H et al. Distinct contributions of rod, cone, and melanopsin photoreceptors to encoding irradiance. Neuron 2010; 66: 417-28.
17. Berson DM. Strange vision: ganglion cells as circadian photoreceptors. Trends Neurosci 2003; 26: 314-20.
18. Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science 2002; 295: 1070-3.
19. Brown TM, Wynne J, Piggins HD, Lucas RJ. Multiple hypothalamic cell populations encoding distinct visual information. J Physiol 2011
20. Czeisler CA, Allan JS, Strogatz SH, et al. Bright light resets the human circadian pacemaker independent of the timing of the sleepwake cycle. Science 1986; 233: 667-71.
21. Viswanathan M, Laitinen JT, Saavedra JM. Vascular melatonin receptors. Biol Signals 1993; 2: 221-7.
22. Krauchi K, Cajochen C, Pache M, Flammer J, Wirz-Justice A. Thermoregulatory effects of melatonin in relation to sleepiness. Chronobiol Int 2006; 23: 475-84.
23. Kin NM, Nair NP, Schwartz G, Thavundayil JX, Annable L. Secretion of melatonin in healthy elderly subjects: a longitudinal study. Ann N Y Acad Sci 2004; 1019: 326-9.
24. Magri F, Sarra S, Cinchetti W et al. Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians. J Pineal Res 2004; 36: 256-61.
25. Zhao ZY, Xie Y, Fu YR, Bogdan A, Touitou Y. Aging and the circadian rhythm of melatonin: a cross-sectional study of Chinese subjects 30-110 yr of age. Chronobiol Int 2002; 19: 1171-82.
26. Scheuermaier K, Laffan AM, Duffy JF. Light exposure patterns in healthy older and young adults. J Biol Rhythms 2010; 25: 113-22.
27. Kunz D, Schmitz S, Mahlberg R et al. A new concept for melatonin deficit: on pineal calcification and melatonin excretion. Neuropsychopharmacology 1999; 21: 765-72.
28. Munch M, Knoblauch V, Blatter K et al. Age-related attenuation of the evening circadian arousal signal in humans. Neurobiol Aging 2005; 26: 1307-19.
29. Cajochen C, Munch M, Knoblauch V, Blatter K, Wirz-Justice A. Age-related changes in the circadian and homeostatic regulation of human sleep. Chronobiol Int 2006; 23: 461-74.
30. Tozawa T, Mishima K, Satoh K, Echizenya M, Shimizu T, Hishikawa Y. Stability of sleep timing against the melatonin secretion rhythm with advancing age: clinical implications. J Clin Endocrinol Metab 2003; 88: 4689-95.
31. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005; 27: 101-10.
32. Alarma-Estrany P, Pintor J. Melatonin receptors in the eye: location, second messengers and role in ocular physiology. Pharmacol Ther 2007; 113: 507-22.
33. Launay JM, Lamaitre BJ, Husson HP, Dreux C, Hartmann L, Da Prada M. Melatonin synthesis by rabbit platelets. Life Sci 1982; 31: 1487-94.
34. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010; 62: 343-80.
35. Mailliet F, Ferry G, Vella F et al. Characterization of the melatoninergic MT3 binding site on the NRH: quinone oxidoreductase 2 enzyme. Biochem Pharmacol 2005; 71: 74-88.
36. Nosjean O, Ferro M, Coge F et al. Identification of the melatoninbinding site MT3 as the quinone reductase 2. J Biol Chem 2000; 275: 31311-7.
37. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9: 11-24.
38. Redman J, Armstrong S, Ng KT. Free-running activity rhythms in the rat: entrainment by melatonin. Science 1983; 219: 1089-91.
39. Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992; 9: 380-92.
40. Cajochen C, Krauchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 2003; 15: 432-7.
41. Cajochen C, Krauchi K, Wirz-Justice A. The acute soporific action of daytime melatonin administration: effects on the EEG during wakefulness and subjective alertness. J Biol Rhythms 1997; 12: 636-43.
42. van Geijlswijk IM, Korzilius HP, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep 2010; 33: 1605-14.
43. Lewy AJ, Emens JS, Lefler BJ, Yuhas K, Jackman AR. Melatonin entrains free-running blind people according to a physiological dose-response curve. Chronobiol Int 2005; 22: 1093-106.
44. Krauchi K, Cajochen C, Wirz-Justice A. A relationship between heat loss and sleepiness: effects of postural change and melatonin administration. J Appl Physiol 1997; 83: 134-9.
45. Cuesta M, Clesse D, Pevet P, Challet E. New light on the serotonergic paradox in the rat circadian system. J Neurochem 2009; 110: 231-43.
46. Challet E, Turek FW, Laute M, Van Reeth O. Sleep deprivation decreases phase-shift responses of circadian rhythms to light in the mouse: role of serotonergic and metabolic signals. Brain Res 2001; 909: 81-91.
47. Gannon RL, Millan MJ. Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythms. Psychopharmacology (Berl) 2007; 195: 325-32.
48. Youngstedt SD, Kripke DF, Elliott JA. Circadian phase-delaying effects of bright light alone and combined with exercise in humans. Am J Physiol Regul Integr Comp Physiol 2002; 282: R259-66.
49. Kennaway DJ, Moyer RW. MK-801 administration blocks the effects of a 5-HT(2A/2C) agonist on melatonin rhythmicity and cfos induction in the suprachiasmatic nucleus. Brain Res 1999; 845: 102-6.
50. Varcoe TJ, Kennaway DJ. Activation of 5-HT2C receptors acutely induces Per1 gene expression in the rat SCN in vitro. Brain Res 2008; 1209: 19-28.
51. Luo AH, Aston-Jones G. Circuit projection from suprachiasmatic nucleus to ventral tegmental area: a novel circadian output pathway. Eur J Neurosci 2009; 29: 748-60.
52. Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110: 135-70.
53. Aloyo VJ, Berg KA, Clarke WP, Spampinato U, Harvey JA. Inverse agonism at serotonin and cannabinoid receptors. Prog Mol Biol Transl Sci 2010; 91: 1-40.
54. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010; 9: 628-42.
55. Association AP. The Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition. American Psychiatric Association; 1994.
56. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 2004; 65 Suppl 16: 27-32.
57. Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry 2005; 66: 1254-69.
58. Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 2006; 21 Suppl 1: S25-9.
59. Baldwin DS, Papakostas GI. Symptoms of fatigue and sleepiness in major depressive disorder. J Clin Psychiatry 2006; 67 Suppl 6: 9-15.
60. Benedetti F, Barbini B, Campori E, Fulgosi MC, Pontiggia A, Colombo C. Sleep phase advance and lithium to sustain the antidepressant effect of total sleep deprivation in bipolar depression: new findings supporting the internal coincidence model? J Psychiatr Res 2001; 35: 323-9.
61. Serretti A, Benedetti F, Mandelli L et al. Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. Am J Med Genet B Neuropsychiatr Genet 2003; 121B: 35-8.
62. Serretti A, Gaspar-Barba E, Calati R et al. 3111T/C clock gene polymorphism is not associated with sleep disturbances in untreated depressed patients. Chronobiol Int 2010; 27: 265-77.
63. Calati R, Gaspar-Barba E, Yukler A, Serretti A. T3111C clock single nucleotide polymorphism and mood disorders: a metaanalysis. Chronobiol Int 2010; 27: 706-21.
64. Lee KY, Song JY, Kim SH et al. Association between CLOCK 3111T/C and preferred circadian phase in Korean patients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1196-201.
65. Tolle R, Goetze U. On the daily rhythm of depression symptomatology. Psychopathology 1987; 20: 237-49.
66. Joyce PR, Porter RJ, Mulder RT, et al. Reversed diurnal variation in depression: associations with a differential antidepressant response, tryptophan: large neutral amino acid ratio and serotonin transporter polymorphisms. Psychol Med 2005; 35: 511-7.
67. Almeida OP, Pfaff JJ. Sleep complaints among older general practice patients: association with depression. Br J Gen Pract 2005; 55: 864-6.
68. [Magnusson A, Partonen T. The diagnosis, symptomatology, and epidemiology of seasonal affective disorder. CNS Spectr 2005; 10: 625-34; quiz 1-14.
69. Posener JA, DeBattista C, Williams GH, Chmura Kraemer H, Kalehzan BM, Schatzberg AF. 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry 2000; 57: 755-60.
70. Terman M. Evolving applications of light therapy. Sleep Med Rev 2007; 11: 497-507.
71. Wirz-Justice A, Benedetti F, Berger M et al. Chronotherapeutics (light and wake therapy) in affective disorders. Psychol Med 2005; 35: 939-44.
72. Xu Y, Padiath QS, Shapiro RE et al. Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. Nature 2005; 434: 640-4.
73. Shirayama M, Shirayama Y, Iida H et al. The psychological aspects of patients with delayed sleep phase syndrome (DSPS). Sleep Med 2003; 4: 427-33.
74. Bara AC, Arber S. Working shifts and mental health--findings from the British Household Panel Survey (1995-2005). Scand J Work Environ Health 2009; 35: 361-7.
75. Drake CL, Roehrs T, Richardson G, Walsh JK, Roth T. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep 2004; 27: 1453-62.
76. Pandi-Perumal SR, Moscovitch A, Srinivasan V, Spence DW, Cardinali DP, Brown GM. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine. Prog Neurobiol 2009; 88: 264-71.
77. McClung CA. Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 2007; 114: 222-32.
78. Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol 2008; 23: 571-85.
79. Claustrat B, Chazot G, Brun J, Jordan D, Sassolas G. A chronobiological study of melatonin and cortisol secretion in depressed subjects: plasma melatonin, a biochemical marker in major depression. Biol Psychiatry 1984; 19: 1215-28.
80. Karadottir R, Axelsson J. Melatonin secretion in SAD patients and healthy subjects matched with respect to age and sex. Int J Circumpolar Health 2001; 60: 548-51.
81. Rabe-Jablonska J, Szymanska A. Diurnal profile of melatonin secretion in the acute phase of major depression and in remission. Med Sci Monit 2001; 7: 946-52.
82. Szymanska A, Rabe-Jablonska J, Karasek M. Diurnal profile of melatonin concentrations in patients with major depression: relationship to the clinical manifestation and antidepressant treatment. Neuro Endocrinol Lett 2001; 22: 192-8.
83. Bunney JN, Potkin SG. Circadian abnormalities, molecular clock genes and chronobiological treatments in depression. Br Med Bull 2008; 86: 23-32.
84. Emens JS, Yuhas K, Rough J, Kochar N, Peters D, Lewy AJ. Phase angle of entrainment in morning- and evening-types under naturalistic conditions. Chronobiol Int 2009; 26: 474-93.
85. Souetre E, Salvati E, Belugou JL et al. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res 1989; 28: 263-78.
86. Szuba MP, Guze BH, Baxter LRJ. Electroconvulsive therapy increases circadian amplitude and lowers core body temperature in depressed subjects. Biol Psychiatry 1997; 42: 1130-7.
87. Koenigsberg HW, Teicher MH, Mitropoulou V et al. 24-h Monitoring of plasma norepinephrine, MHPG, cortisol, growth hormone and prolactin in depression. J Psychiatr Res 2004; 38: 503-11.
88. Rahman SA, Marcu S, Kayumov L, Shapiro CM. Altered sleep architecture and higher incidence of subsyndromal depression in low endogenous melatonin secretors. Eur Arch Psychiatry Clin Neurosci 2010; 260: 327-35.
89. Boivin DB. Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders. J Psychiatry Neurosci 2000; 25: 446-58.
90. Dallaspezia S, Benedetti F. Melatonin, circadian rhythms, and the clock genes in bipolar disorder. Curr Psychiatry Rep 2009; 11: 488-93.
91. Goodwin F Jamison K. Manic-depressive illness. New York: Oxford University press; 1990
92. Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry 2000; 48: 593-604.
93. Frank E. Interpersonal and social rhythm therapy: a means of improving depression and preventing relapse in bipolar disorder. J Clin Psychol 2007; 63: 463-73.
94. Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995; 346: 541-4.
95. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep 1995; 18: 598-603.
96. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007; 16: 372-80.
97. Wade AG, Ford I, Crawford G et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010; 8: 51.
98. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat 2009; 5: 341-54.
99. Wade AG, Ford I, Crawford G et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007; 23: 2597-605.
100. Wade AG, Crawford G, Ford I et al. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin 2011; 27: 87-98.
101. Jan JE, Tai J, Hahn G, Rothstein RR. Melatonin replacement therapy in a child with a pineal tumor. J Child Neurol 2001; 16: 139-40.
102. Mittal VA, Karlsgodt K, Zinberg J, Cannon TD, Bearden CE. Identification and treatment of a pineal region tumor in an adolescent with prodromal psychotic symptoms. Am J Psychiatry 2010; 167: 1033-7.
103. Quera-Salva MA, Hartley S, Claustrat B, Brugieres L. Circadian rhythm disturbances associated with psychiatric symptoms in a patient with a pineal region tumor. Am J Psychiatry 2011; 168: 99-100.
104. Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry 1998; 155: 1119-21.
105. Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci 2000; 25: 48-52.
106. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006; 7: 17-24.
107. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005; 28: 303-7.
108. Cajochen C. TAK-375 Takeda. Curr Opin Investig Drugs 2005; 6: 114-21.
109. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007; 3: 495-504.
110. Neubauer DN. A review of ramelteon in the treatment of sleep disorders. Neuropsychiatr Dis Treat 2008; 4: 69-79.
111. Hirai K, Kita M, Ohta H, et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms 2005; 20: 27-37.
112. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48: 301-10.
113. McElroy SL, Winstanley EL, Martens B, et al. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. Int Clin Psychopharmacol 2011; 26: 48-53.
114. Yous S, Andrieux J, Howell HE, et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem 1992; 35: 1484-6.
115. Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954-4.
116. Martinet L, Guardiola-Lemaitre B, Mocaer E. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol Biochem Behav 1996; 54: 713-8.
117. Redman JR, Guardiola-Lemaitre B, Brown M, Delagrange P, Armstrong SM. Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology (Berl) 1995; 118: 385-90.
118. Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Redman JR. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav 1993; 46: 45-9.
119. Leproult R, Van Onderbergen A, L'hermite-Baleriaux M, Van Cauter E, Copinschi G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf) 2005; 63: 298-304.
120. Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010; 71: 109-20.
121. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010; 24: 479-99.
122. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebocontrolled dose range study. Int Clin Psychopharmacol 2002; 17: 239-47.
123. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10: 661-73.
124. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93-100.
125. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723-32.
126. Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 2010; 25: 305-14.
127. Goodwin GM, Emsley R, Rembry S, Rouillon F. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 1128-37.
128. Goodwin G, F R, R E. Long-term treatment with agomelatine: prevention of relapse in patients with major depressive disorder over 10 months. Eur Neuropsychopharmacol 2009; 18: S338.
129. Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007; 10: 691-6.
130. Lopes MC, Quera-Salva MA, Guilleminault C. Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine). Sleep Med 2007; 9: 33-41.
131. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22: 283-91.
132. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28: 329-33.
133. Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol 2010; 24: 111-20.
134. Kozian R, Syrbe G. [QTc prolongation during treatment with agomelatine]. Psychiatr Prax 2010; 37: 405-7.
135. Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009; 26: 997-1012.
136. Acikalin A, Satar S, Avc A, Topal M, Kuvandk G, Sebe A. QTc intervals in drug poisoning patients with tricyclic antidepressants and selective serotonin reuptake inhibitors. Am J Ther 2010; 17: 30-3.
137. de Boer RA, van Dijk TH, Holman ND, van Melle JP. QT interval prolongation after sertraline overdose: a case report. BMC Emerg Med 2005; 5: 5.
138. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004; 42: 277-85.
139. Stott DJ, Robertson JI, McLenachan JM, Ball SG. Effects of shortterm ketanserin treatment on the QT interval and vagal function in healthy subjects. J Auton Pharmacol 1989; 9: 45-51.
140. Kaye GC, Mehta D, Wafa S, Camm AJ. Acute electrophysiologic effects of an HT2-serotonin antagonist, ketanserin, in humans. Cardiovasc Drugs Ther 1990; 4: 1157-60.
141. Zemlan FP, Mulchahey JJ, Scharf MB, Mayleben DW, Rosenberg R, Lankford A. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 2005; 66: 384-90.
142. Nickelsen T, Samel A, Vejvoda M, Wenzel J, Smith B, Gerzer R. Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift: results of a placebo-controlled trial. Chronobiol Int 2002; 19: 915-36.
143. Rajaratnam SM, Polymeropoulos MH, Fisher DM et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleeptime shift: two randomised controlled multicentre trials. Lancet 2009; 373: 482-91.
144. Tian SW, Laudon M, Han L, et al. Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models. Acta Pharmacol Sin 2010; 31: 775-783.
145. Yalkinoglu O, Zisapel N, Nir T Phase-I study of the safety, tolerability, pharmacokinetics and sleep promoting activity of Neu-P11, a novel putative insomnia drug in healthy humans. Sleep 2010; 33: A220.
146. Westrich L, Sprouse J. Circadian rhythm dysregulation in bipolar disorder. Curr Opin Investig Drugs 2010; 11: 779-87.
147. Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circadian basis of winter depression. Proc Natl Acad Sci U S A 2006; 103: 7414-9.